Skip to main content
. 2021 Feb 22;206(7):1609–1617. doi: 10.4049/jimmunol.2000991

FIGURE 3.

FIGURE 3.

Susceptibility to in vitro HIV-1 infection was reduced in MDMs treated with rhERAPs. MDMs from 15 HCs were treated with 100 ng/ml of rhERAP1, rhERAP2, or rhERAP1+rhERAP2 and in vitro HIV infected with a R5 HIV1Ba-L. P24 concentration was measured by ELISA in 6 d post–in vitro HIV-1–infected supernatants. Mean values and SEM are shown. *p < 0.05.